Fawzy, M.S.; Alenezy, A.; Jishu, J.A.; Khan, I.; Dessouky, A.; Abdelmaksoud, A.; Limbach, K.E.; Toraih, E.A.
Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study. Cancers 2025, 17, 1593.
https://doi.org/10.3390/cancers17091593
AMA Style
Fawzy MS, Alenezy A, Jishu JA, Khan I, Dessouky A, Abdelmaksoud A, Limbach KE, Toraih EA.
Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study. Cancers. 2025; 17(9):1593.
https://doi.org/10.3390/cancers17091593
Chicago/Turabian Style
Fawzy, Manal S., Awwad Alenezy, Jessan A. Jishu, Issa Khan, Ahmad Dessouky, Ahmed Abdelmaksoud, Kristen E. Limbach, and Eman A. Toraih.
2025. "Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study" Cancers 17, no. 9: 1593.
https://doi.org/10.3390/cancers17091593
APA Style
Fawzy, M. S., Alenezy, A., Jishu, J. A., Khan, I., Dessouky, A., Abdelmaksoud, A., Limbach, K. E., & Toraih, E. A.
(2025). Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study. Cancers, 17(9), 1593.
https://doi.org/10.3390/cancers17091593
